Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation

BACKGROUND: Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation‐predominant irritable bowel syndrome (IBS‐C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS‐C clinical trials, recommending a composite endpoi...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, L., Chey, W. D., Drossman, D., Losch‐Beridon, T., Wang, M., Lichtlen, P., Mareya, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Lubiprostone and Irritable Bowel Syndrome
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215520/
https://www.ncbi.nlm.nih.gov/pubmed/27669680
http://dx.doi.org/10.1111/apt.13807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215520/
https://www.ncbi.nlm.nih.gov/pubmed/27669680
http://dx.doi.org/10.1111/apt.13807

Ejemplares similares